PEA

SciSparc Ltd. announced a Japanese patent application for a novel pain management therapy. The application covers a combination of paracetamol and palmitoylethanolamide (PEA) designed to enhance pain and fever relief while potentially reducing side effects, including liver damage. This synergistic approach aims to improve treatment outcomes for various pain types and leverage the body’s endocannabinoid system.